Global access to biological disease-modifying drugs

Rachel McCormick¹, Rebecca Hotchkin², Jessica Manson³

Affiliations

¹ School of Medical Education, King's College London, London SE1 1UL, UK; Universities Allied for Essential Medicines, Berlin, Germany. Electronic address: rachelmcc126@gmail.com.
² School of Medical Education, King's College London, London SE1 1UL, UK; Universities Allied for Essential Medicines, Berlin, Germany.
³ Department of Rheumatology, University College London Hospitals NHS Foundation Trust, London, UK.

PMID: 38294015
DOI: 10.1016/S2665-9913(22)00160-6

Global access to biological disease-modifying drugs

Rachel McCormick et al. Lancet Rheumatol. 2022 Jul.

. 2022 Jul;4(7):e465.

doi: 10.1016/S2665-9913(22)00160-6.

Authors

Rachel McCormick¹, Rebecca Hotchkin², Jessica Manson³

Affiliations

¹ School of Medical Education, King's College London, London SE1 1UL, UK; Universities Allied for Essential Medicines, Berlin, Germany. Electronic address: rachelmcc126@gmail.com.
² School of Medical Education, King's College London, London SE1 1UL, UK; Universities Allied for Essential Medicines, Berlin, Germany.
³ Department of Rheumatology, University College London Hospitals NHS Foundation Trust, London, UK.

PMID: 38294015
DOI: 10.1016/S2665-9913(22)00160-6

No abstract available

PubMed Disclaimer

Conflict of interest statement

RM and RH are national co-directors of Universities Allied for Essential Medicines UK. However, views presented in this paper are not necessarily shared with Universities Allied for Essential Medicines Europe or the academic institutions the authors are affiliated with. We declare no other competing interests.

Similar articles

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region.
Kaló Z, Vokó Z, Östör A, Clifton-Brown E, Vasilescu R, Battersby A, Gibson E. Kaló Z, et al. J Mark Access Health Policy. 2017 Jul 5;5(1):1345580. doi: 10.1080/20016689.2017.1345580. eCollection 2017. J Mark Access Health Policy. 2017. PMID: 28740623 Free PMC article.
Real-life data of survival and reasons for discontinuation of biological disease-modifying drugs 'in' rheumatoid arthritis.
Gomides APM, de Albuquerque CP, Santos ABV, Bértolo MB, Júnior PL, Giorgi RDN, Radominski SC, Resende Guimarães MFB, Bonfiglioli KR, de Fátima Lobato da Cunha Sauma M, Pereira IA, Brenol CV, da Mota LMH, Pinheiro GDRC. Gomides APM, et al. Int J Clin Pharm. 2021 Jun;43(3):737-742. doi: 10.1007/s11096-020-01171-5. Epub 2020 Oct 21. Int J Clin Pharm. 2021. PMID: 33085040
Effect of biologic disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis who hope to become mothers.
Shimada H, Kameda T, Kanenishi K, Miyatake N, Nakashima S, Wakiya R, Kato M, Miyagi T, Mansour MMF, Hata T, Kadowaki N, Dobashi H. Shimada H, et al. Clin Rheumatol. 2019 May;38(5):1453-1458. doi: 10.1007/s10067-019-04450-3. Epub 2019 Feb 7. Clin Rheumatol. 2019. PMID: 30729372
An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis.
Tenti S, Bruyère O, Cheleschi S, Reginster JY, Veronese N, Fioravanti A. Tenti S, et al. Ther Adv Musculoskelet Dis. 2023 Mar 14;15:1759720X231158618. doi: 10.1177/1759720X231158618. eCollection 2023. Ther Adv Musculoskelet Dis. 2023. PMID: 36937821 Free PMC article. Review.
The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery.
Caraceni P, Abraldes JG, Ginès P, Newsome PN, Sarin SK. Caraceni P, et al. J Hepatol. 2021 Jul;75 Suppl 1:S118-S134. doi: 10.1016/j.jhep.2021.01.024. J Hepatol. 2021. PMID: 34039483 Review.

See all similar articles

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Global access to biological disease-modifying drugs

Affiliations

Global access to biological disease-modifying drugs

Authors

Affiliations

Conflict of interest statement

Similar articles

Publication types

LinkOut - more resources

Full Text Sources